Growing Patient Interest in Integrative Approaches for PCOS
Recent surveys and clinical observations indicate a rising trend among individuals with Polycystic Ovary Syndrome (PCOS) seeking adjunctive, functional medicine strategies that combine lifestyle interventions, physical rehabilitation, and nutrition with emerging biological research. PCOS affects approximately 8–13% of reproductive-aged women (Dumesic et al., 2015) and is associated with insulin resistance, hyperandrogenism, and chronic low-grade inflammation. Many patients explore supportive therapies beyond conventional hormonal management. This narrative review positions the topic within an adjunctive, functional medicine framework, including physical therapy and nutrition, while summarizing early research on umbilical cord‑derived mesenchymal stem cell (UC‑MSC) paracrine signaling and differentiation capacity relevant to PCOS pathophysiology.
Metabolic Signaling and Androgen Modulation in PCOS: The Research Context
Current research indicates that hyperinsulinemia promotes ovarian androgen hypersecretion and disrupts folliculogenesis (Escobar-Morreale, 2018). Evidence from preclinical models suggests that UC‑MSCs release paracrine factors—including cytokines, growth factors, and extracellular vesicles—that may influence insulin sensitivity and local inflammatory profiles. For example, a rodent study observed that systemic administration of UC‑MSCs was associated with improved glucose tolerance and reduced serum testosterone levels (Xie et al., 2019). These effects have been attributed to modulation of the PI3K/AKT signaling pathway and reduction of ovarian oxidative stress. However, all findings remain preliminary and derived from animal models.
UC‑MSC Paracrine Effects on Insulin Sensitivity: Preclinical Observations
Early in vitro and in vivo research has explored the hypothesis that UC‑MSC‑derived secretome may improve insulin signaling in peripheral tissues. A study using dehydroepiandrosterone (DHEA)‑induced PCOS rats reported that UC‑MSC transplantation was associated with enhanced insulin receptor substrate‑1 (IRS‑1) phosphorylation and lower homeostatic model assessment of insulin resistance (HOMA‑IR) values compared to controls (Li et al., 2021). Additionally, conditioned media from UC‑MSCs reduced pro‑inflammatory cytokines (TNF‑α, IL‑6) in cultured granulosa cells. Although these observations are promising, they have not yet been replicated in human trials, and the clinical relevance remains uncertain.
Differentiation into Theca‑Like Cells: In Vitro Investigations
A niche area of investigation involves the differentiation capacity of mesenchymal stem cells into steroidogenic cell lineages. In a controlled laboratory setting, researchers have demonstrated that human UC‑MSCs can be induced to express key theca cell markers (e.g., CYP17A1, STAR) when cultured with specific differentiation media (Wang et al., 2020). These in vitro experiments suggest that UC‑MSCs possess phenotypic plasticity; however, functional androgen production by differentiated theca‑like cells has been limited and requires further molecular characterization. No in vivo differentiation into theca cells has been reported, and this strategy is strictly experimental.
UC‑MSCs within the Integrative Medicine Framework
Within an integral medicine framework, UC‑MSCs are best understood as a potential adjunctive biological support rather than a standalone treatment. Current evidence suggests that any putative benefits of UC‑MSC administration in PCOS would likely derive from paracrine immunomodulation and metabolic signaling modulation, not from direct cell replacement. Integrative approaches for PCOS continue to prioritize evidence‑based lifestyle modifications: structured physical therapy/rehabilitation to improve metabolic fitness, nutrition counseling (low glycemic index diets, anti‑inflammatory patterns), and conventional medical management (insulin sensitizers, hormonal contraceptives). As of March 2026, no MSC‑based therapy is approved for PCOS by any regulatory agency (FDA, EMA, COFEPRIS).
Research Limitations and Adjunctive Role
This narrative review emphasizes that all described UC‑MSC strategies remain within early research stages. None of the mechanisms discussed are approved for clinical use in PCOS. All MSC therapies should be considered adjunctive—requiring rigorous, well‑controlled human trials before any efficacy claim can be established. The current body of evidence consists predominantly of in vitro studies and small animal models. Large, randomized clinical trials are necessary to determine safety, optimal dosing, and potential patient subgroups that might derive benefit.
This article summarizes research only. None of the described strategies are approved yet for clinical use. All MSC therapies are still categorized as adjunctive and require further clinical validation.
References
- Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and clinical manifestations of polycystic ovary syndrome. Endocrine Reviews, 36(5), 487–525.
- Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270–284.
- Xie, Q., Xiong, X., Xiao, N., He, L., & Peng, Y. (2019). Mesenchymal stem cells alleviate DHEA-induced polycystic ovary syndrome in rats by regulating ovarian oxidative stress and inflammation. Stem Cell Research & Therapy, 10(1), 285.
- Li, Y., Liu, Y., Liu, S., Gao, M., & Wang, D. (2021). Human umbilical cord mesenchymal stem cells ameliorate insulin resistance in PCOS rats through paracrine mechanism. Journal of Molecular Endocrinology, 66(3), 179–191.
- Wang, H., Zhang, Y., & Chen, J. (2020). In vitro differentiation of mesenchymal stem cells into theca‑like cells: a preliminary study. Reproductive Biology and Endocrinology, 18(1), 45.